EGFR and lung cancer: Given that these ligands may represent alternative targets for therapeutic inhibition of EGFR signaling in lung cancer [66] and the growing importance of immune effectors in lung cancer pathogenesis, the specific cell types that express Ereg and Areg and their functional role in tumorigenesis are areas of interest in the future use of the SPC-IGFIR model.